HPV状态对原发灶不明头颈癌的预后与治疗结局的影响
该回顾性研究基于美国国家癌症数据库2010至2013年978例成人原发灶不明头颈癌(HNCUP)患者,评估HPV相关与HPV阴性患者的治疗结局。HPV相关患者3年生存率94.8%,显著优于HPV阴性患者的80.3%。HPV阴性cN2/cN3患者单纯放疗较放化疗生存更差,而HPV相关cN2/cN3患者各治疗模式生存相当。
要点
- HPV相关HNCUP患者3年生存率94.8%,显著优于HPV阴性者的80.3%。
- HPV阴性cN2/cN3患者单纯放疗较放化疗生存更差(HR 5.507,P=0.005)。
- HPV相关cN2/cN3患者手术、放疗、放化疗等模式生存无显著差异。
核心结论
- 肿瘤HPV状态对HNCUP具有显著预后价值,应在未来降治疗研究中加以考虑。
- HPV阴性cN2/cN3患者降治疗为单纯放疗可能降低生存,而HPV阳性患者降治疗值得进一步研究。
研究设计与样本
- 回顾性研究,纳入美国国家癌症数据库2010至2013年诊断的978例成人HNCUP患者。
- 采用多因素Cox生存回归及单因素Kaplan-Meier分析。
主要发现
- HPV相关患者3年生存率为94.8%(标准误1.0),HPV阴性患者为80.3%(标准误2.9)。
- HPV阴性cN2/cN3患者中,单纯根治性放疗较根治性放化疗与生存下降相关(风险比5.507,P=0.005)。
- HPV相关cN2/cN3患者中,单纯手术、手术加辅助放疗、手术加辅助放化疗、根治性放化疗及根治性放疗的生存差异无统计学意义。
临床怎么用
- HNCUP患者应检测肿瘤HPV状态以辅助预后判断。
- HPV阴性cN2/cN3患者应谨慎采用单纯放疗的降治疗策略。
- HPV阳性cN2/cN3患者的降治疗可在研究背景下进一步探索。
局限性
- 证据等级为4级。
- 为回顾性研究,治疗选择可能受多种因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Approximately 3% to 9% of head and neck cancer presents with a metastatic node and no identifiable primary tumor. These cases of head and neck carcinoma of unknown primary (HNCUP) present a therapeutic challenge. Therapy of this disease varies based on factors such as institutional, surgeon, and patient preference. Evidence demonstrating the outcomes associated with these therapies for HNCUP is limited, and among the available series, the tumor human papillomavirus (HPV) status is often ignored. Treatment deintensification has been proposed for a subset of these patients. We aim to evaluate the treatment-related outcomes for HPV-associated and HPV-negative HNCUP. METHODS: A retrospective study of 978 adult HNCUP diagnosed from 2010 to 2013 in the NCDB was conducted. Multivariate Cox survival regressions as well as univariate Kaplan-Meier analyses were conducted. RESULTS: Patients with HPV-associated disease had superior survival, with a 3-year survival of 94.8% (standard error [SE]: 1.0), compared with 80.3% (SE: 2.9) among those with HPV-negative disease. Among HPV-negative patients with clinical nodal classification (cN)2/cN3 disease, treatment with definitive radiotherapy alone compared to definitive chemoradiotherapy was associated with diminished survival (hazard ratio 5.507, P = 0.005). Among patients with HPV-associated cancer and cN2/cN3 disease, all treatments (surgery alone, surgery with adjuvant radiotherapy, surgery with adjuvant chemoradiotherapy, definitive chemoradiotherapy, definitive radiotherapy) resulted in statistically equivalent survival. CONCLUSION: Tumor HPV status has a significant prognostic value for HNCUP and should be considered in future studies of treatment deintensification in this group. Treatment deintensification to radiotherapy alone in cN2/cN3 cases may result in poorer patient survival for HPV-negative patients, whereas it may be a promising option for further investigation in HPV-positive patients. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:684-691, 2019.
引用
- Cheraghlou S, Torabi SJ, Husain ZA, et al. HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. Laryngoscope. 2018. PMID: 30151832. doi:10.1002/lary.27475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。